Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2025-08-28 Regulatory Filings
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cardiff Oncology, Inc. Form S-8 is used to register securities to be offered to employees under employee benefit plans, such as stock option plans or omnibus incentive plans. The text includes details about the registration of shares under the 2021 Omnibus Equity Incentive Plan, references to prior S-8 filings, and legal indemnification provisions for directors and officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a full registration statement filing.
2025-08-28 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-14 English
4
Director's Dealing
2025-07-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text mentions the announcement of financial results for the second quarter ended June 30, 2025, and includes press releases and presentation materials related to clinical trial data and company highlights. The document does not contain detailed financial statements or comprehensive financial analysis itself but rather announces and furnishes exhibits such as press releases and presentations. The length is 4737 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings like Form 8-K that do not fit other specific categories.
2025-07-29 English
10-Q
Interim / Quarterly Report Q2 2025
2025-07-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-07-29 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.